The Latest Cardiac and Vascular News
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of […]
Experience Continues to Show CCM Therapy Addresses Clinical Need in Treating Heart Failure MARLTON, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, announced the 100th implant in China, signifying the opportunity for its innovative Optimizer® […]
IDENTIFY Study Results Published in PLOS ONE WASHINGTON–(BUSINESS WIRE)–CorVista Health, Inc, a digital health company dedicated to improving cardiovascular disease diagnosis, announces the publishing of the IDENTIFY Study in PLOS ONE, the multicenter validation of a machine learned (ML) phase space electro-mechanical pulse wave analysis to predict elevated left ventricular end […]
List Recognizes Tech Breakthroughs Across Industries That Promise to Transform the Future CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, today announced that it has been named to Fast Company’s second annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industries—from agriculture and environment […]
Platform simplifies life support, making life-saving technology more accessible to hospitals and critically ill patients LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S. Food and Drug Administration (FDA) for LifeSPARC™, the Company’s […]
Study of the Verve RPD™ Renal Pelvic Denervation System Shows 20.3 mm Hg Reduction in Blood Pressure in Patients with Uncontrolled Hypertension PHOENIX–(BUSINESS WIRE)–Verve Medical, Inc. (“Verve”) today announced the detailed results from a feasibility trial evaluating a novel ablation therapy that achieved therapeutically significant blood pressure (“BP”) reduction for […]
McDermott + Bull Partner Ken Dropiewski talks with Endeavour Vision Partner Rob Barmann about his journey from corporate development to venture capital.
Patent Opens Pathway to Disruptive Ischemia and Arrhythmia Detection Product in Multi-billion Dollar Wearables Device Market SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today that its patent for a […]
Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo) Subjects Using a Thiazide Diuretic (Approximately Half of the Study Population) Showed a Mean Placebo-Adjusted Reduction in Systolic Blood […]
The first real-world biometrics data platform for continuous and episodic remote patient monitoring now supports Roche, OMRON, Garmin, and other wearable medical devices to power virtual healthcare applications. CAMPBELL, Calif., Nov. 16, 2022 /PRNewswire/ — Vivalink, a leading provider of digital healthcare solutions, announces physiological data from a wide range of the world’s leading […]
